Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 4/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.34 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.34 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7381643 | 1.00 | MAPT (0.36) | MAPTMEN1KMT2ANPSR1CYP2C19 | |
| SCHEMBL7377448 | 0.83 | HSP90AB1 (0.35) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL7377447 | 0.83 | HSP90AB1 (0.35) | MAPTKMT2AALDH1A1NPC1RAB9A | |
| Medorinone SCHEMBL10816601 | 0.82 | PDE3B (0.56) | KMT2AALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL10811980 | 0.81 | HTT (0.35) | MAPTKMT2ACYP2C19ALDH1A1HPGD | |
| SCHEMBL10813620 | 0.81 | HTT (0.35) | MAPTKMT2ACYP2C19ALDH1A1HPGD | |
| SCHEMBL10377662 | 0.81 | RECQL (0.43) | MAPTMEN1KMT2ANPSR1CYP2C19 | |
| SCHEMBL10377663 | 0.81 | RECQL (0.43) | MAPTMEN1KMT2ANPSR1CYP2C19 | |
| SCHEMBL10377563 | 0.80 | ALDH1A1 (0.40) | MAPTMEN1KMT2ANPSR1CRHBP | |
| SCHEMBL10377561 | 0.80 | ALDH1A1 (0.40) | MAPTMEN1KMT2ANPSR1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0101952-B1 | 5-ALKYL-1,6-NAPHTHYRIDIN-2(1H)-ONES, INTERMEDIATES, THEIR PREPARATION AND THEIR CARDIOTONIC USE | STERLING DRUG INC. (US) | 1987-09-23 | — | — | EP | claimed |
| US-4559347-A | 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and preparation thereof | STERLING DRUG INC. (US) | 1985-12-17 | — | — | US | claimed |
| EP-0101952-A1 | 5-Alkyl-1,6-naphthyridin-2(1H)-ones, intermediates, their preparation and their cardiotonic use | STERLING DRUG INC. (US) | 1984-03-07 | — | — | EP | claimed |
| US-4415580-A | Certain 2-(1H)-pyridinones cardiotonic compositions containing same and method of using same | STERLING DRUG INC. (US) | 1983-11-15 | — | — | US | claimed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8258301-B2 | Urotensin II receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| WO-2008144268-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| EP-0134535-B1 | 1,6-NAPHTHYRIDIN DERIVATIVES USEFUL AS CARDIOTONICS AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1988-10-26 | — | — | EP | disclosed |
| EP-0101952-B1 | 5-ALKYL-1,6-NAPHTHYRIDIN-2(1H)-ONES, INTERMEDIATES, THEIR PREPARATION AND THEIR CARDIOTONIC USE | STERLING DRUG INC. (US) | 1987-09-23 | — | — | EP | disclosed |
| US-4604399-A | 5-methyl(or ethyl)-1,6-naphthyridin-2(1H)-one 6-oxides, their preparation and the cardiotonic use thereof | STERLING DRUG INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4559347-A | 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and preparation thereof | STERLING DRUG INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4532247-A | Increases cardiac contractility | STERLING DRUG INC. (US) | 1985-07-30 | — | — | US | disclosed |
| US-4517190-A | 5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof | STERLING DRUG INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0134535-A1 | 1,6-Naphthyridin derivatives useful as cardiotonics and preparation thereof | STERLING DRUG INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| EP-0101952-A1 | 5-Alkyl-1,6-naphthyridin-2(1H)-ones, intermediates, their preparation and their cardiotonic use | STERLING DRUG INC. (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4415580-A | Certain 2-(1H)-pyridinones cardiotonic compositions containing same and method of using same | STERLING DRUG INC. (US) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121051-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, AGTR1, AGTR2 | MAPT 182/4885MEN1 1823/4885KMT2A 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.